boule-shutterstock-com-cherry-
Boule / Shutterstock.com
24 March 2016PharmaJoachim Wachenfeld and Oswin Ridderbusch

A second bite at the cherry

Second medical use claims have a long-standing history in European Patent Office (EPO) case law. As is well known, the first ever decision of the EPO’s Enlarged Board of Appeal confirmed the patentability of second medical use claims when written in the so-called Swiss-type format. The Enlarged Board in that 1984 decision, G5/83, held that protection was available for “specified new and inventive therapeutic application[s]”. In the years that followed the technical boards of appeal controversially discussed what exactly was meant by the “specified therapeutic applications” referred to by the Enlarged Board.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
15 October 2026   A dispute over missing experimental data and patent disclosures draws to a close as Boehringer and Dr Reddy’s deliver their final arguments. The court’s decision could bring greater clarity to the UK approach to plausibility and determine whether Dr Reddy’s can move ahead with its proposed generic launch.
Pharma
14 October 2026   Efforts to bring a generic cyanide poisoning treatment to market have suffered a setback after a US judge rejected challenges to three patents and criticised the drugmaker’s interpretation of the treatment’s chemical composition.
Pharma
13 October 2026   Generic challengers have scored a win against the Danish company after an appeals board revoked a key patent covering the cardiovascular use of semaglutide. The decision strips away another layer of protection as generic manufacturers hunt down the semaglutide franchise.